SCR-LIP-000607 · Claim · machine-readable JSON →
Ultrasound, body-composition and lymphatic imaging measures are reported to discriminate lipedema from controls or related conditions.
General proposition consolidated from 8 earlier single-paper claims; each study's own result is shown as its finding.
Claim at a glance
- Type
- clinical association
- Knowledge state
- Emerging
- Evidence certainty
- low (GRADE)
- Evidence
- 8 source(s) · by Amato
- Answers
- 1 question(s)
- Dates
- 2026-11-20 → 2026-11-20
Structured evidence, machine-compiled — not a verdict.
Evidence over time
Evidence (8)
- Ultrasound criteria for lipedema diagnosis — Amato et al. (2021) ✓ verified — consistent · cross sectional · n=89 · 2021 · risk of bias: moderate · reading confidence: high
Ultrasound in 89 participants: pretibial subcutaneous thickness AUC 0.908-0.909; cutoff ~11.7 mm (sensitivity 0.77-0.79, specificity 0.92-0.96); 81% of lipedema patients overweight/obese by BMI alone.
81% of lipedema group overweight/obese by BMI alone - Body Composition Assessment by Dual-Energy X-Ray Absorptiometry: A Useful Tool for the Diagnosis of Lipedema — Buso et al. (2022) ✓ verified — consistent · cross sectional · 2022 · reading confidence: high
DXA leg fat/total fat index distinguished lipedema from controls: AUC 0.90, sensitivity 0.95, specificity 0.73 at cutoff 0.383, across BMI strata.
The article directly evaluates DXA's ability to differentiate lipedema from controls and characterize its fat distribution, providing specific diagnostic accuracy metrics that support DXA's discriminative role. [grade capped moderate->low per curated Oxford N4] - Lipedema and Dercum's Disease: A New Application of Bioimpedance — Crescenzi et al. (2019) ✓ verified — consistent · cross sectional · 2019 · reading confidence: high
Bioimpedance spectroscopy distinguished lipedema from Dercum's disease (leg/arm ratio, p<0.001) and stage 1 lipedema from matched controls (p=0.01).
The question concerns clinical criteria and stage/type classification systems and their reliability. This study uses the conventional clinical stage classification (stage 1-3) as a reference and proposes an objective bioimpedance biomarker [grade capped moderate->low per curated Oxford N4] - Lower Limb Lipedema–Superficial Lymph Flow, Skin Water Concentration, Skin and Subcutaneous Tissue Elasticity — Zaleska et al. (2023) ✓ verified — consistent · cross sectional · 2023 · reading confidence: moderate
50 lipedema vs 50 controls: slower superficial lymph flow on ICG lymphography (upper calf reached in 8% vs 56%, p<0.0001), higher foot skin water and greater subcutaneous stiffness.
Controlled cross-sectional study using lymphoscintigraphy, ICG lymphography, and tissue measurements to differentiate lipedema limbs from normal controls, directly addressing whether imaging/measurement modalities can characterize lipedema, [grade capped moderate->low per curated Oxford N4] - The role of IL-6 gene polymorphisms in the risk of lipedema — Di Renzo L et al. (2020) ✓ verified — consistent · cross sectional · 2020 · reading confidence: moderate
Case-control: IL-6 rs1800795 G allele OR 5.92; DXA indices (lower WHR, higher lower-limb fat %) with genotyping proposed for differential diagnosis from obesity.
The article proposes composite body-composition indices and IL-6 genotyping as promising tools for diagnosis and differential analysis of lipedema, indirectly supporting that screening/diagnostic tools can help identify it; however it does - Reply letter to the editor regarding ultrasound examination for en-suite measurements in lipedema — Amato & Saucedo (2022) ✓ verified — consistent · review · 2022 · reading confidence: moderate
“Medições próprias (Amato et al. 2021): espessura média do tecido subcutâneo na coxa — 20,9 mm (lipedema) vs 12,67 mm (controles)”
Reply letter states lipedema is frequently underdiagnosed and defends ultrasound cutoffs; mean subcutaneous thigh thickness 20.9 mm in lipedema vs 12.67 mm in controls.
A correspondence/reply letter explicitly asserting that lipedema is frequently underdiagnosed and discussing ultrasound criteria as a diagnostic tool; it directly addresses both parts of the question but is opinion/letter-level evidence. - Lipedema: pathophysiological insights and therapeutic strategies — An update for dermatologists (2026) ✓ verified — refining · review · 2026 · reading confidence: high
“addressing the persistent underdiagnosis and misdiagnosis of the condition”
Review describes ultrasound cutoffs (pretibial >=11.7 mm, sensitivity 0.77-0.79, specificity up to 0.96) and DXA ratio >=0.384 as auxiliary tools for borderline cases, not yet externally validated.
The review explicitly addresses persistent underdiagnosis and describes imaging screening/diagnostic aids with cutoffs and performance, supporting the affirmative but noting the ultrasound cutoffs are not yet externally validated (a caveat) - Lymphoscintigraphic Findings in Patients With Lipedema: A Systematic Review. — Mortada H, Alsaif MA, AlJohani A, Altuwaijri AM, Alshomer F. (2026) ✓ verified — refining · review · 2026 · reading confidence: high
“Lymphoscintigraphy findings were normal in 61.4% of patients with lipedema. Tortuous lymph vessels were the most common abnormality (56.8%), followed by collateral lymph vessels (49.1%) and popliteal node visualization (44.0%). Dermal backflow (3.8%) and secondary lymphedema (11.8%) were less freque”
Systematic review of 7 studies: lymphoscintigraphy normal in 61.4% of lipedema patients; tortuous vessels 56.8%, dermal backflow 3.8%; methodological heterogeneity.
The review reports lymphoscintigraphy patterns in lipedema (mostly normal or overload signs, low dermal backflow) that help distinguish it from lymphedema, but stresses methodological heterogeneity and lack of standardized protocols, qualif
Context (PECO)
Answers these questions
Gaps & caveats
Change log
- 2026-11-20 — created_by_consolidation · general proposition consolidated from SQ-LIP-000004